Research Article

Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

Figure 3

Time to alleviation of fever, nonspecific symptoms, and nasal/throat/chest symptoms. The duration of the main ARI symptoms in the Ergoferon group was significantly less in comparison with the placebo group. Notes. ; ; .